No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL
Thomas R. O'Brien, Jordan J. Feld, Shyam Kottilil, Ruth M. Pfeiffer – 16 October 2015
Continued controversy over the safety of beta‐blockers in decompensated cirrhosis
Agustín Albillos, Javier Martínez, Luis Téllez – 16 October 2015
Reply
Koji Miyanishi, Masayoshi Kobune, Junji Kato – 16 October 2015
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease
Chiara Rosso, Lavinia Mezzabotta, Melania Gaggini, Federico Salomone, Roberto Gambino, Andrea Marengo, Francesca Saba, Ester Vanni, Ramy Younes, Chiara Saponaro, Emma Buzzigoli, Gian Paolo Caviglia, Maria Lorena Abate, Antonina Smedile, Mario Rizzetto, Maurizio Cassader, Amalia Gastaldelli, Elisabetta Bugianesi – 16 October 2015 – Surrogate indexes of insulin resistance and insulin sensitivity are widely used in nonalcoholic fatty liver disease (NAFLD), although they have never been validated in this population.
Bidirectional transendothelial migration of monocytes across hepatic sinusoidal endothelium shapes monocyte differentiation and regulates the balance between immunity and tolerance in liver
Henning W. Zimmermann, Tony Bruns, Chris J. Weston, Stuart M. Curbishley, Evaggelia Liaskou, Ka‐Kit Li, Yazid J. Resheq, Paul W. Badenhorst, David H. Adams – 16 October 2015 – Monocytes are versatile cells that can fulfill proinflammatory and anti‐inflammatory functions when recruited to the liver. Recruited monocytes differentiate into tissue macrophages and dendritic cells, which sample antigens and migrate to lymph nodes to elicit T‐cell responses.
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease
Chiara Rosso, Lavinia Mezzabotta, Melania Gaggini, Federico Salomone, Roberto Gambino, Andrea Marengo, Francesca Saba, Ester Vanni, Ramy Younes, Chiara Saponaro, Emma Buzzigoli, Gian Paolo Caviglia, Maria Lorena Abate, Antonina Smedile, Mario Rizzetto, Maurizio Cassader, Amalia Gastaldelli, Elisabetta Bugianesi – 16 October 2015 – Surrogate indexes of insulin resistance and insulin sensitivity are widely used in nonalcoholic fatty liver disease (NAFLD), although they have never been validated in this population.
Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease
Hyunjoo Kwon, Kyoungsub Song, Chang Han, Weina Chen, Ying Wang, Srikanta Dash, Kyu Lim, Tong Wu – 16 October 2015 – Hedgehog (Hh) signaling plays a critical role in liver development, regeneration, injury repair, and carcinogenesis. Activation of Hh signaling has been observed in patients with nonalcoholic fatty liver diseases (NAFLD); however, the pathobiological function and regulatory mechanism of hepatic Hh signaling in the pathogenesis of NAFLD remain to be further defined.
Akt‐mediated foxo1 inhibition is required for liver regeneration
Montse Pauta, Noemi Rotllan, Ana Fernández‐Hernando, Cedric Langhi, Jordi Ribera, Mingjian Lu, Loreto Boix, Jordi Bruix, Wladimiro Jimenez, Yajaira Suárez, David A. Ford, Angel Baldán, Morris J. Birnbaum, Manuel Morales‐Ruiz, Carlos Fernández‐Hernando – 16 October 2015 – Understanding the hepatic regenerative process has clinical interest as the effectiveness of many treatments for chronic liver diseases is conditioned by efficient liver regeneration.
Liver capsule: Age‐influenced hepatic immune priming determines HBV infection fate: Implications from mouse to man
Jean Publicover, Jillian M. Jespersen, Audra J. Johnson, Stephen L. Nishimura, Amanda Goodsell, Adil E. Wakil, Philip Rosenthal, Eric Pai, Lia Avanesyan, Stewart Cooper, Jody L. Baron – 12 October 2015
Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient
Joel P. Wedd, Eric Nordstrom, Trevor Nydam, Janette Durham, Michael Zimmerman, Thor Johnson, W. Thomas Purcell, Scott W. Biggins – 12 October 2015 – Liver transplantation can provide definitive cure for patients with cirrhosis and hepatocellular carcinoma (HCC) when used appropriately. Advances in the management of HCC have allowed improved control of HCC while waiting for liver transplantation and new approaches to candidate selection particularly with regard to tumor burden and downstaging protocols.